サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1530993

線維筋痛症治療の世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2034年）

Fibromyalgia Treatment Market (Treatment Type: Medications and Therapies, and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 123 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
線維筋痛症治療の世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2034年）
出版日: 2024年06月11日
発行: Transparency Market Research
ページ情報: 英文 123 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の線維筋痛症治療市場について、2024～2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018～2034年までの世界の線維筋痛症治療市場の収益と予測を提供しています。また、2024～2034年までの世界の線維筋痛症治療市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、産業リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、線維筋痛症治療市場を推察しました。

市場スナップショット
2023年の市場規模 19億米ドル
2034年の市場規模 29億米ドル
CAGR 3.8%

当レポートでは、世界の線維筋痛症治療市場の競合情勢について調査しています。世界の線維筋痛症治療市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の線維筋痛症治療市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測、2017～2031年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要合併・買収
  • COVID-19による産業への影響

第6章 世界の市場分析と予測：治療タイプ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：治療タイプ別、2017～2031年
    • 医薬品
    • 治療
  • 市場魅力分析：治療タイプ別

第7章 世界の市場分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：流通チャネル別、2017～2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場魅力分析：流通チャネル別

第8章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017～2031年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析：地域別

第9章 北米の市場分析と予測

第10章 欧州の市場分析と予測

第11章 アジア太平洋の市場分析と予測

第12章 ラテンアメリカの市場分析と予測

第13章 中東・アフリカの市場分析と予測

第14章 競合情勢

  • 市場企業 - 競合マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Pfizer Inc.
    • Eli Lilly and Company
    • AbbVie Inc.
    • Tonix Pharmaceuticals
    • Aptinyx Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Sun Pharmaceutical Industries Limited
    • Astellas Pharma Inc.
    • Nipro Corporation
図表

List of Tables

  • Table 01: Global Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 02: Global Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Region, 2017-2031
  • Table 04: North America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Country, 2017-2031
  • Table 05: North America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 06: North America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 07: Europe Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 08: Europe Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 09: Europe Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 10: Asia Pacific Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 11: Asia Pacific Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 12: Asia Pacific Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Latin America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Latin America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 15: Latin America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Middle East & Africa Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Middle East & Africa Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
  • Table 18: Middle East & Africa Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Fibromyalgia Treatment Market Size (US$ Bn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global Fibromyalgia Treatment Market Revenue (US$ Bn), by Treatment Type, 2022
  • Figure 03: Global Fibromyalgia Treatment Market Value Share, by Treatment Type, 2022
  • Figure 04: Global Fibromyalgia Treatment Market Revenue (US$ Bn), by Distribution Channel, 2022
  • Figure 05: Global Fibromyalgia Treatment Market Value Share, by Distribution Channel, 2022
  • Figure 06: Global Fibromyalgia Treatment Market Value Share, by Region, 2022
  • Figure 07: Global Fibromyalgia Treatment Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 08: Global Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 09: Global Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 10: Global Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 11: Global Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 12: Global Fibromyalgia Treatment Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 13: Global Fibromyalgia Treatment Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 14: North America Fibromyalgia Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 15: North America Fibromyalgia Treatment Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 16: North America Fibromyalgia Treatment Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 17: North America Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 18: North America Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 19: North America Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 20: North America Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 21: Europe Fibromyalgia Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 22: Europe Fibromyalgia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 23: Europe Fibromyalgia Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 24: Europe Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 25: Europe Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 26: Europe Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 27: Europe Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 28: Asia Pacific Fibromyalgia Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 29: Asia Pacific Fibromyalgia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 30: Asia Pacific Fibromyalgia Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 31: Asia Pacific Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 32: Asia Pacific Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Asia Pacific Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 34: Asia Pacific Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 35: Latin America Fibromyalgia Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 36: Latin America Fibromyalgia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 37: Latin America Fibromyalgia Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 38: Latin America Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 39: Latin America Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 40: Latin America Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 41: Latin America Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 42: Middle East & Africa Fibromyalgia Treatment Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 43: Middle East & Africa Fibromyalgia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 44: Middle East & Africa Fibromyalgia Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 45: Middle East & Africa Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 46: Middle East & Africa Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 47: Middle East & Africa Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 48: Middle East & Africa Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
目次
Product Code: TMRGL22697

Fibromyalgia Treatment Market - Scope of Report

TMR's report on the global fibromyalgia treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global fibromyalgia treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global fibromyalgia treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the fibromyalgia treatment market.

Market Snapshot
Market Value in 2023US$ 1.9 Bn
Market Value in 2034US$ 2.9 Bn
CAGR3.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global fibromyalgia treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global fibromyalgia treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global fibromyalgia treatment market.

The report delves into the competitive landscape of the global fibromyalgia treatment market. Key players operating in the global fibromyalgia treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global fibromyalgia treatment market profiled in this report.

Key Questions Answered in Global fibromyalgia treatment Market Report:

  • What is the sales/revenue generated by fibromyalgia treatment across all regions during the forecast period?
  • What are the opportunities in the global fibromyalgia treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Fibromyalgia Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global fibromyalgia treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global fibromyalgia treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global fibromyalgia treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fibromyalgia Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Fibromyalgia Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Fibromyalgia Treatment Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 6.3.1. Medications
      • 6.3.1.1. Pain Relievers
      • 6.3.1.2. Anti-Depressants
      • 6.3.1.3. Anti-Seizure Drugs
    • 6.3.2. Therapies
      • 6.3.2.1. Physical Therapy
      • 6.3.2.2. Occupational Therapy
      • 6.3.2.3. Counselling
  • 6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Fibromyalgia Treatment Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Fibromyalgia Treatment Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2017-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Fibromyalgia Treatment Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 9.3.1. Medications
      • 9.3.1.1. Pain Relievers
      • 9.3.1.2. Anti-Depressants
      • 9.3.1.3. Anti-Seizure Drugs
    • 9.3.2. Therapies
      • 9.3.2.1. Physical Therapy
      • 9.3.2.2. Occupational Therapy
      • 9.3.2.3. Counselling
  • 9.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Value Forecast, by Country, 2017-2031
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Treatment Type
    • 9.6.2. By Distribution Channel
    • 9.6.3. By Country

10. Europe Fibromyalgia Treatment Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 10.3.1. Medications
      • 10.3.1.1. Pain Relievers
      • 10.3.1.2. Anti-Depressants
      • 10.3.1.3. Anti-Seizure Drugs
    • 10.3.2. Therapies
      • 10.3.2.1. Physical Therapy
      • 10.3.2.2. Occupational Therapy
      • 10.3.2.3. Counselling
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Treatment Type
    • 10.6.2. By Distribution Channel
    • 10.6.3. By Country/Sub-region

11. Asia Pacific Fibromyalgia Treatment Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 11.3.1. Medications
      • 11.3.1.1. Pain Relievers
      • 11.3.1.2. Anti-Depressants
      • 11.3.1.3. Anti-Seizure Drugs
    • 11.3.2. Therapies
      • 11.3.2.1. Physical Therapy
      • 11.3.2.2. Occupational Therapy
      • 11.3.2.3. Counselling
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Treatment Type
    • 11.6.2. By Distribution Channel
    • 11.6.3. By Country/Sub-region

12. Latin America Fibromyalgia Treatment Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 12.3.1. Medications
      • 12.3.1.1. Pain Relievers
      • 12.3.1.2. Anti-Depressants
      • 12.3.1.3. Anti-Seizure Drugs
    • 12.3.2. Therapies
      • 12.3.2.1. Physical Therapy
      • 12.3.2.2. Occupational Therapy
      • 12.3.2.3. Counselling
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Treatment Type
    • 12.6.2. By Distribution Channel
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa Fibromyalgia Treatment Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 13.3.1. Medications
      • 13.3.1.1. Pain Relievers
      • 13.3.1.2. Anti-Depressants
      • 13.3.1.3. Anti-Seizure Drugs
    • 13.3.2. Therapies
      • 13.3.2.1. Physical Therapy
      • 13.3.2.2. Occupational Therapy
      • 13.3.2.3. Counselling
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Treatment Type
    • 13.6.2. By Distribution Channel
    • 13.6.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Pfizer Inc.
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Eli Lilly and Company
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. AbbVie Inc.
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Tonix Pharmaceuticals
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Aptinyx Inc.
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Teva Pharmaceutical Industries Ltd.
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Novartis AG
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Sun Pharmaceutical Industries Limited
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Astellas Pharma Inc.
      • 14.3.9.1. Company Overview
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Nipro Corporation
      • 14.3.10.1. Company Overview
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Financial Overview
      • 14.3.10.5. Strategic Overview